ArticleThe Permanente journal2017
Incidence of Pulmonary Arterial Hypertension in Patients with Psoriasis: A Retrospective Cohort Study.
Article in The Permanente journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Chronic Inflammation as the Underlying Mechanism of the Development of Lung Diseases in Psoriasis: A Systematic Review.International journal of molecular sciences · 2022Pooled it
- Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology.Anais brasileiros de dermatologia · 2019Guideline
- Pooled it
- Serum Levels of Human Neutrophil Peptides 1-3 (HNP1-3) as Potential Biomarkers in Psoriasis and Associated Comorbidities.Biomedicines · 2025Article
- Unmasking Pulmonary Parenchymal Changes in Psoriasis Patients: A Radiological Perspective.Medicina (Kaunas, Lithuania) · 2025Article
- A study on the genetic comorbidity between autoimmune diseases and pulmonary hypertension: an observational study and POST-GWAS analysis.International journal of medical sciences · 2025Observational
- Clinical evaluation of code-based algorithms to identify patients with pulmonary arterial hypertension in healthcare databases.Pulmonary circulation · 2024Article
- Pulmonary comorbidities in psoriasis are associated with a high risk of respiratory failure.The Journal of international medical research · 2023Article
- Galectin-7 downregulation in lesional keratinocytes contributes to enhanced IL-17A signaling and skin pathology in psoriasis.The Journal of clinical investigation · 2021Article
- Identifying Patients with Pulmonary Arterial Hypertension Using Administrative Claims Algorithms.Annals of the American Thoracic Society · 2019Review
- Evaluation of code-based algorithms to identify pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension patients in large administrative databases.Pulmonary circulationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextInflammatory signaling may play an important role in the pathogenesis of pulmonary arterial hypertension (PAH).
objectiveTo assess the incidence of PAH in patients with mild and severe psoriasis compared with their respective controls.
designFrom January 2004 to November 2012, we performed a retrospective cohort study of patients with psoriasis in the Kaiser Permanente Southern California Health Plan. Patients with an International Classification of Diseases, Ninth Revision Clinical Modification diagnostic code for psoriasis (696.1) or psoriatic arthritis (696.0) without a prior diagnosis of primary PAH (416.0) or secondary PAH (416.8) were eligible for inclusion. Patients who had never received a diagnosis of psoriasis were frequency-matched by age, sex, and race to form the control cohorts.
main outcome measuresIncidence of PAH in patients with psoriasis compared with matched controls.
resultsThere were 10,115 patients with mild psoriasis, 3821 with severe psoriasis, and 69,360 matched controls. On multivariable analysis, there was a significantly increased risk of PAH developing in the severe psoriasis cohort vs their controls (hazard ratio = 1.46, 95% confidence interval = 1.09-1.94).
conclusionThe systemic inflammatory process underlying psoriasis may be a cause for an increased risk of PAH, but there are numerous secondary causes of PAH, some of which were not accounted for in our study. Further prospective, randomized controlled trials are necessary to establish psoriasis as a risk factor for PAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.